Podcasts about chronic lymphocytic leukemia cll

Dr Alessandra Ferrajoli (University of Texas MD Anderson Cancer Center, US) provides an in-depth cumulative review of hypertension management in patients with Chronic Lymphocytic Leukemia (CLL) and other hematologic malignancies treated with Acalabrutinib. This podcast explores the mechanisms, incidence and clinical implications of treatment-related hypertension, offering evidence-based strategies to optimise cardiovascular care for this patient population.

Welcome to the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. John Allan from New York Presbyterian Hospital to discuss the latest highlights from ASH 2024, focusing on Chronic Lymphocytic Leukemia (CLL). We dived into three key studies: 1.⁠ ⁠SEQUOIA Update: Discover how this study led to the approval of Zanubrutinib in the frontline setting and its impressive progression-free survival rates compared to traditional chemotherapy. 2.⁠ ⁠AMPLIFY Study: Learn about the exciting combination of Acalabrutinib with Venetoclax and Obinutuzumab, and how it may pave the way for the first oral doublet/triplet combination approval in the U.S. 3.⁠ ⁠Ongoing Trials: We touch on the CELESTIAL TN-CLL trial and the promising combination of Zanubrutinib with Sonrotoclax, a new BCL-2 inhibitor. Additionally, we discuss the evolving role of CAR-T therapy in CLL, especially for patients who have progressed through multiple lines of treatment. Join us for an insightful discussion on the future of CLL treatment options, the importance of balancing efficacy and side effects, and the exciting developments in the field. Don't forget to check out our other ASH and SABCS 2024 discussions! Subscribe to stay updated on the latest in oncology research and treatments! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Kerry A. Rogers, MD, The Ohio State University, Columbus, OH Recorded on October 29, 2024 Kerry A. Rogers, MD Associate Professor Division of Hematology The Ohio State University Columbus, OH Tune in for this comprehensive overview of Chronic Lymphocytic Leukemia (CLL) with Dr. Kerry Rogers from The Ohio State University. She covers key risk factors, signs and symptoms, and the critical decision-making process between monitoring and initiating treatment. Also explored are treatment goals with consideration to how strategies may vary for different subsets of patients, and discussion on new therapies. Additionally, Dr. Rogers addresses side effect management and resources available to support both patients and their families. Listen to this informative episode today!

- Overview of Chronic Lymphocytic Leukemia (CLL) - Key Questions to Ask & Re-Ask Your Health Care Team About Adherence - The Critical Role of Caregivers in Adherence - The Importance of Adherence: Taking Your Treatment on Schedule - Discussion of Barriers to Taking Your Treatment & Pills on Schedule - Tips to Overcome These Barriers - Planning Ahead: Lead Time in Refilling Prescriptions, Weekends, Travel, Special Occasions, and Holidays - Practical Help from Family, Partners, Caregivers & Others - The Role of the Pharmacy & Pharmacist in Reminding You About Prescription Refills - Suggestions for People Living with CLL & Their Caregivers to Cope with Taking Charge of Your Treatment Schedule - Necessary Support for the Caregivers - Questions for Our Panel of Experts

- Overview of Chronic Lymphocytic Leukemia (CLL) - Key Questions to Ask & Re-Ask Your Health Care Team About Adherence - The Critical Role of Caregivers in Adherence - The Importance of Adherence: Taking Your Treatment on Schedule - Discussion of Barriers to Taking Your Treatment & Pills on Schedule - Tips to Overcome These Barriers - Planning Ahead: Lead Time in Refilling Prescriptions, Weekends, Travel, Special Occasions, and Holidays - Practical Help from Family, Partners, Caregivers & Others - The Role of the Pharmacy & Pharmacist in Reminding You About Prescription Refills - Suggestions for People Living with CLL & Their Caregivers to Cope with Taking Charge of Your Treatment Schedule - Necessary Support for the Caregivers - Questions for Our Panel of Experts

- Overview of Chronic Lymphocytic Leukemia (CLL) - Key Questions to Ask & Re-Ask Your Health Care Team About Adherence - The Critical Role of Caregivers in Adherence - The Importance of Adherence: Taking Your Treatment on Schedule - Discussion of Barriers to Taking Your Treatment & Pills on Schedule - Tips to Overcome These Barriers - Planning Ahead: Lead Time in Refilling Prescriptions, Weekends, Travel, Special Occasions, and Holidays - Practical Help from Family, Partners, Caregivers & Others - The Role of the Pharmacy & Pharmacist in Reminding You About Prescription Refills - Suggestions for People Living with CLL & Their Caregivers to Cope with Taking Charge of Your Treatment Schedule - Necessary Support for the Caregivers - Questions for Our Panel of Experts

Featuring perspectives from Dr John N Allan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, including the following topics: Introduction (0:00) First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (11:44) The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL (18:08) Toxicities and Other Practical Considerations with Venetoclax-Based Treatment (25:17) The Selection and Sequencing of Therapies for Relapsed/Refractory CLL (35:45) The Tolerability of Available Bruton Tyrosine Kinase (BTK) Inhibitors (40:43) The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax (48:48) Bispecific Antibodies as a Treatment Option for Non-Hodgkin Lymphoma (1:04:19) Cytokine Release Syndrome and Neurotoxicity with Bispecific Antibodies (1:06:25) Other Tolerability and Toxicity Issues with Bispecific Antibody Therapy (1:10:44) Bispecific Antibodies for the Management of Follicular Lymphoma (1:18:19) The Role of Bispecific Antibody Therapy in the Treatment of Diffuse Large B-Cell Lymphoma (1:24:17) Other Practical Considerations with the Use of Bispecific Antibodies (1:40:59) NCPD information and select publications

- Overview of CLL - Caring for Your Loved One with CLL - Taking on the Role of Caregiving - Your Important Role in Decision Making - Challenges in Communicating with the Health Care Team - Your Role in Adherence: Weekends, Holidays & Vacations - Coping with Each Day, On Special Occasions, Anniversaries & Birthdays - Managing Family, Friends & Traditions - Long-Distance Caregiving - Self-Care Tips for Managing Stress - Questions for Our Panel of Experts

- Overview of CLL - Caring for Your Loved One with CLL - Taking on the Role of Caregiving - Your Important Role in Decision Making - Challenges in Communicating with the Health Care Team - Your Role in Adherence: Weekends, Holidays & Vacations - Coping with Each Day, On Special Occasions, Anniversaries & Birthdays - Managing Family, Friends & Traditions - Long-Distance Caregiving - Self-Care Tips for Managing Stress - Questions for Our Panel of Experts

- Overview of CLL - Caring for Your Loved One with CLL - Taking on the Role of Caregiving - Your Important Role in Decision Making - Challenges in Communicating with the Health Care Team - Your Role in Adherence: Weekends, Holidays & Vacations - Coping with Each Day, On Special Occasions, Anniversaries & Birthdays - Managing Family, Friends & Traditions - Long-Distance Caregiving - Self-Care Tips for Managing Stress - Questions for Our Panel of Experts

- Review of Chronic Lymphocytic Leukemia - Significant Role of Testing in Informing Treatment Choices - First-Line Treatment Options - Treatment for Relapsed & Refractory CLL - Re-Testing Importance in Determining Treatment for 2nd & 3rd Line Treatments - Current Perspectives on New & Emerging Treatments of CLL - Updates on Clinical Trials & Their Significance for CLL - Key Questions to Ask & Re-Ask Your CLL Health Care Team - Practical & Psychosocial Support to Cope with CLL - Questions for Our Panel of Experts

- Review of Chronic Lymphocytic Leukemia - Significant Role of Testing in Informing Treatment Choices - First-Line Treatment Options - Treatment for Relapsed & Refractory CLL - Re-Testing Importance in Determining Treatment for 2nd & 3rd Line Treatments - Current Perspectives on New & Emerging Treatments of CLL - Updates on Clinical Trials & Their Significance for CLL - Key Questions to Ask & Re-Ask Your CLL Health Care Team - Practical & Psychosocial Support to Cope with CLL - Questions for Our Panel of Experts

- Review of Chronic Lymphocytic Leukemia - Significant Role of Testing in Informing Treatment Choices - First-Line Treatment Options - Treatment for Relapsed & Refractory CLL - Re-Testing Importance in Determining Treatment for 2nd & 3rd Line Treatments - Current Perspectives on New & Emerging Treatments of CLL - Updates on Clinical Trials & Their Significance for CLL - Key Questions to Ask & Re-Ask Your CLL Health Care Team - Practical & Psychosocial Support to Cope with CLL - Questions for Our Panel of Experts

- Overview of CLL - Current Treatment Options - New Perspectives & Emerging Treatment Approaches - Clinical Trial Updates: How Research Increases Your Treatment Options - Guidelines to Prepare for Telehealth/Telemedicine Appointments with Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Practical Support to Cope with CLL - Questions for Our Panel of Experts

- Overview of CLL - Current Treatment Options - New Perspectives & Emerging Treatment Approaches - Clinical Trial Updates: How Research Increases Your Treatment Options - Guidelines to Prepare for Telehealth/Telemedicine Appointments with Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Practical Support to Cope with CLL - Questions for Our Panel of Experts

- Overview of CLL - Current Treatment Options - New Perspectives & Emerging Treatment Approaches - Clinical Trial Updates: How Research Increases Your Treatment Options - Guidelines to Prepare for Telehealth/Telemedicine Appointments with Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Practical Support to Cope with CLL - Questions for Our Panel of Experts

Join us on a heartfelt journey woven by support and education, as we speak to Teresa Altemeyer, who was diagnosed… The post Live Your Life: Navigating Mental Health and Chronic Lymphocytic Leukemia (CLL) first appeared on The Bloodline with LLS.

Join us on a heartfelt journey woven by support and education, as we speak to Teresa Altemeyer, who was diagnosed… The post Live Your Life: Navigating Mental Health and Chronic Lymphocytic Leukemia (CLL) first appeared on The Bloodline with LLS.

In this informative podcast episode, the Oncology Brothers delve into the world of hematologic malignancies, focusing specifically on Chronic Lymphocytic Leukemia (CLL). Dr. Nitin Jain from MD Anderson Cancer Center joins the discussion, sharing insights on the latest treatment options and guidelines for CLL. The episode covers essential topics such as determining when a patient with CLL needs treatment, the minimal workup required for scans and biopsies, and the decision-making process between time-limited venetoclax and long-term BTK inhibitors. Dr. Jain also discusses the use of second-generation BTK inhibitors like Acalabrutinib and Zanabrutinib, as well as the recent approvals of Partibrutinib and CAR-T  for third-line treatment. Tune in to gain a deeper understanding of CLL treatment strategies, managing side effects, and the evolving landscape of hematologic malignancies. Don't miss out on this insightful conversation that will benefit both healthcare professionals and patients navigating CLL treatment options. Stay informed and stay tuned for upcoming episodes on multiple myeloma and myelofibrosis with the Oncology Brothers. Subscribe now to stay updated on the latest in oncology care.

In this heartfelt episode of "Cancer Actually F**king Sucks," Geoff Grubbs shares his journey with Chronic Lymphocytic Leukemia (CLL), offering a candid account of the highs and lows he's experienced. Hosted by Abigail, the conversation delves into Geoff's medical decisions, emotional challenges, and the vital role of community support. Geoff highlights the importance of organizations like the CLL Society and the Lymphoma Research Foundation, which provide invaluable resources and connections for those navigating similar paths. Join the discussion for an insightful exploration of living with CLL and the power of resilience in facing life's toughest battles. To learn more about the CLL Society, visit https://cllsociety.org/, and to get information about CLL Society Support Groups, head to https://cllsociety.org/programs-and-support/cll-specific-patient-support-groups/. Don't forget to rate and review the podcast on Spotify and Apple Podcasts, and follow us on Instagram at @canceractuallysuckspod for more inspiring content! --- Send in a voice message: https://podcasters.spotify.com/pod/show/cancer-actually-sucks/message

We're joined by Dr. Chris Hillis, MD, MSc, FRCPC, Hematologist, and Chief of Oncology at Hamilton Health Sciences. In this engaging discussion, Dr. Hillis explores the role of our immune system, blood cells, and diagnosis and treatment options for those living with Chronic Lymphocytic Leukemia (CLL).The Cancer Assist Show is hosted by Dr. Bill Evans, MD, FRCP, Past President of the Juravinski Hospital and Cancer Centre at HHS. Brought to you by the Cancer Assistance Program – an organization lending support to cancer patients and families of those affected by cancer.---The Cancer Assist Podcast and its content represent the opinions of Dr. Bill Evans and the guests of the podcast. Any views and opinions expressed by Dr. Bill Evans and guests are their own and do not represent those of their places of work. The content of The Cancer Assist Podcast is provided for informational, educational and entertainment purposes only and is not intended as professional medical, legal or any other advice or as a substitute or replacement for any such advice. The Cancer Assistance Program, Dr. Bill Evans and guests make no representations or warranties with respect to the accuracy or validity of any information or content offered or provided by The Cancer Assist Podcast. For any medical needs or concerns, please consult a qualified medical professional. No part of The Cancer Assist Podcast or its content is intended to establish a doctor-patient or any other professional relationship. This podcast is owned and produced by the Cancer Assistance Program.  

The fellas are joined again by Dr. Brian Koffman, a well-known doctor, educator, and clinical professor turned patient has dedicated himself to teaching and helping the Chronic Lymphocytic Leukemia (CLL) community since his diagnosis in 2005. Dr. Koffman believes that his dual status as a physician and patient provides a unique experience and understanding which allows him to provide clear explanations of complex issues and to advocate for his fellow patients and inform his fellow healthcare providers. This week Dr. Koffman joins the boys to chat about CAR-T Cell therapy and all the things you'd ever want to know about drug trials! Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

The fellas are joined again by Dr. Brian Koffman, a well-known doctor, educator, and clinical professor turned patient has dedicated himself to teaching and helping the Chronic Lymphocytic Leukemia (CLL) community since his diagnosis in 2005. Dr. Koffman believes that his dual status as a physician and patient provides a unique experience and understanding which allows him to provide clear explanations of complex issues and to advocate for his fellow patients and inform his fellow healthcare providers. This week Dr. Koffman joins the boys to chat about CAR-T Cell therapy and all the things you'd ever want to know about drug trials! Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chronic Lymphocytic Leukemia (CLL) ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Oncology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://podcasters.spotify.com/pod/show/medbulletsstep1/message

In discussion with Dr. Jeff Sharman, about how to treat CLL. Chronic lymphocytic leukemia course has changed since we have started using BTK inhibitors. Dr. Sharman, director of hematology research at US Oncology Network and Director of Research at Willamette Valley Cancer Institute, was the first to ever give this medication here in the US. We discuss important nuances of CLL management with him, when to proceed with observation vs. treatment, when treating what BTKi to utilize, important side effects one has to keep in mind, and much more.

The CLLSociety.org provides support and education for veterans and others with Chronic Lymphocytic Leukemia (CLL). Bruce Wright, a Vietnam Veteran, has CLL from his days of exposure to Agent Orange. Wright is a patient advocate and educator with the CLL Society. CLL is a condition that impacts the white blood cells. Bruce talks to host Jim Fausone about CLL and the education and advocacy that veterans need when living with CLL.

As geography and regional differences can play a major role in disparities in cancer care, learn how cancer programs can collaborate with local community outreach organizations to improve access to care and support underserved populations. In this episode, CANCER BUZZ speaks with Farrukh T. Awan, MD, MS, professor of Internal Medicine and director of Lymphoid Malignancies at the Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, about their approach to addressing regional barriers to improve care for patients with chronic lymphocytic leukemia. “Time to get to appointments, the driving distance, the traffic issues, the cost of travel, housing/lodging, food—I think those are some of the biggest challenges we see in our patients, especially in our part of the country, where distances are huge and traffic can be an issue in major cities…” – Farrukh Awan, MD, MS   Guest:  Farrukh T. Awan, MD, MS Professor of Internal Medicine Director of Lymphoid Malignancies Program Harold C. Simmons Comprehensive Cancer Center University of Texas Southwestern Medical Center Dallas, TX   This podcast was created in connection with the education program A Regional Approach to Advancing Care for Patients with Chronic Lymphocytic Leukemia. This episode was made possible with support by AstraZeneca, Janssen Oncology, and Pharmacyclics.   Additional Reading/Sources ·       Chronic Lymphocytic Leukemia (CLL) Resources ·       Multidisciplinary Chronic Lymphocytic Leukemia Care (accc-cancer.org) ·       Quality Improvement Case Studies ·       CLL: Models of Effective Care Delivery ·       Podcast EP 104: Addressing Regional Challenges to Equitable Care for Patients with CLL ·       Podcast EP 105: Best Practices in Caring for Patients with CLL in a Post-COVID Era ·       Podcast EP 57: COVID-19 Challenges: Managing Patients with CLL ·       Chronic Lymphocytic Leukemia (CLL) (cancer.org) ·       Addressing Racial Disparities in CLL Care - Patient Empowerment Network (powerfulpatients.org) ·       CLL Resources - CLL Society

Have you or someone you love been diagnosed with cancer? Jeff, a brave warrior in the battle against cancer, was diagnosed with Chronic Lymphocytic Leukemia (CLL) at just 45 years old. Facing the daunting prospects of chemotherapy and immunotherapy, he decided to experiment with an alternative path - Full Extract Cannabis Oil (FECO). Jeff shares his experiences and insights from his seven-year journey with cannabis. He used it as a last resort before starting a six-month trial for leukemia treatment. The results were truly remarkable - he achieved almost five years of remission. Nowadays, Jeff is on a daily oral inhibitor, which he will continue taking until they either cease to work or the side effects become unbearable. His story is not just about survival but also about resilience, exploration, and hope. Throughout our conversation, we explore the details of his journey, the challenges he faced, the victories he celebrated, and the lessons he learned. We discuss the impacts of CLL, the process of producing and using FECO, and the realities of living with the side effects of cancer treatments. Whether you're a patient, a caregiver, a medical professional, or someone interested in alternative approaches to health and wellness, this episode offers a unique perspective on managing a serious illness and embracing life's uncertainties. Tune in to hear Jeff's powerful story as we explore the intersection of Cancer, Chemo, and FECO. Resources: • Well With Cannabis Show Notes - https://emilykylenutrition.com/episode-37/ • Well With Cannabis Community - https://shop.emilykylenutrition.com/product/membership/ Join us today and use the coupon code insider to get 50% off your membership!   

Dr. Koffman, a well-known doctor, educator, and clinical professor turned patient has dedicated himself to teaching and helping the Chronic Lymphocytic Leukemia (CLL) community since his diagnosis in 2005. Dr. Koffman believes that his dual status as a physician and patient provides a unique experience and understanding which allows him to provide clear explanations of complex issues and to advocate for his fellow patients and inform his fellow healthcare providers. The fellas dive into Chronic Cancer VS Acute Cancer and all things Chronic Lymphocytic Leukemia! Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

Dr. Koffman, a well-known doctor, educator, and clinical professor turned patient has dedicated himself to teaching and helping the Chronic Lymphocytic Leukemia (CLL) community since his diagnosis in 2005. Dr. Koffman believes that his dual status as a physician and patient provides a unique experience and understanding which allows him to provide clear explanations of complex issues and to advocate for his fellow patients and inform his fellow healthcare providers. The fellas dive into Chronic Cancer VS Acute Cancer and all things Chronic Lymphocytic Leukemia! Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

Featuring perspectives from Dr John N Allan, Ms Jacqueline Broadway‑Duren, Ms Corinne Hoffman and Dr Adam S Kittai, including the following topics: Introduction (0:00) Overview of Chronic Lymphocytic Leukemia (CLL) (5:20) First-Line Therapy for CLL (32:06) Use of Venetoclax in Combination with an Anti-CD20 Antibody (49:16) Choice of BTK Inhibitor; BTK Inhibitor Toxicity (1:14:33) Noncovalent BTK Inhibitors (1:18:53) CAR T-Cell Therapy; Transformation (1:23:08) NCPD information and select publications

Patients with Chronic Lymphocytic Leukemia (CLL) are considered highly susceptible to bacteria and viruses due to immunocompromisation. Now, in the post-COVID era, we are facing multiple viruses at the same time (i.e., Influenza, RSV, and COVID). It is as important as ever for patients with CLL to continue receiving vaccinations, as well as following safety and preventive measures such as wearing masks and social distancing. CANCER BUZZ spoke to Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, Co-Founder, Executive Vice President, and Chief Medical Officer at the CLL Society in Chula Vista, CA. Hear the most up-to-date best practices, including shared decision-making, regarding treating patients with CLL in this post-COVID era. “The pandemic forced into the spotlight the reality that all CLL patients, regardless of their treatment status, even those who have not been treated, are immunocompromised. Patients had to make shifts in their lifestyle.” “I think it is important that CLL patients realize that the pandemic is not over for the immunocompromised. And the virus that causes Covid infections, is not going away.”  – Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd Co-Founder, Executive Vice President, and Chief Medical Officer CLL Society Chula Vista, CA   Resources: Patients with CLL have a lower risk of death from COVID-19 in the Omicron era (nih.gov) CLL Society Cancer Support Community ClinicalTrials.gov

This week's episode will be focusing on Chronic Lymphocytic Leukemia  (CLL) for health care providers. We will go over all the important details on presentation, diagnosis, prognostic factors, and treatment options.

Please join us as we speak to Dr. Matthew Davids of Dana-Farber Cancer Institute. In this episode, Dr. Davids discusses… The post Achieving Long-term Remission with Chronic Lymphocytic Leukemia (CLL) appeared first on The Bloodline with LLS.

Please join us as we speak to Dr. Matthew Davids of Dana-Farber Cancer Institute. In this episode, Dr. Davids discusses… The post Achieving Long-term Remission with Chronic Lymphocytic Leukemia (CLL) first appeared on The Bloodline with LLS.

Featuring perspectives from Dr Susan O'Brien, including the following topics: Introduction (0:00) Case: A woman in her mid 60s with relapsed Chronic Lymphocytic Leukemia (CLL) who experiences severe headaches on acalabrutinib — Bhavana (Tina) Bhatnagar, DO (12:57) Case: A man in his early 70s with IGHV-unmutated relapsed CLL — Gurveen Kaur, MD (24:43) Case: A man in his late 60s with chronic kidney disease and CLL who develops metastatic rectal cancer while receiving acalabrutinib — G Richard Polkinghorn, MD (31:11) Case: A woman in her mid 60s with relapsed CLL suspicious for Richter's transformation; Del(13q), TP53 and BTK resistance mutation — John N Allan, MD (35:18) Case: A woman in her mid 20s with CLL and transfusion-dependent autoimmune myelofibrosis — Amanda Blackmon, DO, MS (48:47) Journal Club with Susan O'Brien, MD (53:07) CME information and select publications

In this episode, we review the high-yield topic of Chronic Lymphocytic Leukemia (CLL) from the Oncology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

Featuring perspectives from Drs Lindsey Roeker and Jeff Sharman, including the following topics: Introduction (0:00) Current and Future Selection of First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (2:58) Management of Relapsed/Refractory CLL (34:54) Novel Investigational Strategies (47:41) CME information and select publications

Paolo Ghia, MD, PhD, Professor at the Università Vita-Salute San Raffaele, Milan, Italy, discusses the updated, long-term data from the phase 2 CAPTIVATE study. This study evaluated ibrutinib plus venetoclax as a first-line treatment for chronic lymphocytic leukemia (CLL); data from this trial was recently presented at the American Society of Hematology Meeting & Exposition (ASH 2021).

Featuring perspectives from Drs Nitin Jain, Anthony Mato, John Pagel and Jennifer Woyach, moderated by Dr John Allan, including the following topics: Introduction (0:00) Front-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) (5:29) Novel Strategies Combining Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors for CLL (29:04) Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations (51:49) Selection and Sequencing of Available Therapies for R/R Disease (1:13:20) Promising Investigational Agents and Strategies (1:37:44) CME information and select publications

Join us as we speak to Donnie Hill, a patient living with chronic lymphocytic leukemia (CLL) and small cell lymphocytic… The post Anxiety and Hope: Living with Chronic Lymphocytic Leukemia (CLL) first appeared on The Bloodline with LLS.

Join us as we speak to Donnie Hill, a patient living with chronic lymphocytic leukemia (CLL) and small cell lymphocytic… The post Anxiety and Hope: Living with Chronic Lymphocytic Leukemia (CLL) appeared first on The Bloodline with LLS.

Chronic Lymphocytic Leukemia (CLL) is a B-cell malignancy, predominantly affecting the elderly, which is characterized by an accumulation of immunologically... The post Developments in CLL: MRD, LOXO-305 and venetoclax at ASH 2020 appeared first on VJHemOnc.

"The more you invest in understanding what your options are, and where you might go for treatment, the better off you're going to be in the long run. If I had known more early on, I wouldn't have been as sick as I was. That's why I share my story.” - Terry Evans. 20 years ago, Terry was diagnosed with Chronic Lymphocytic Leukemia (CLL). He joined a small support group called the CLL Society and helped grow the group from 5 individuals in a living room to an international organization with 35 chapters throughout the US and Canada. Thankfully, CLL treatment has advanced tremendously. He is now cancer free and has seen the birth of 11 grandchildren. You can read more about Terry's CLL journey at terrysclljourney.blogspot.com.***If you enjoyed the podcast, please leave a short review. It takes only a minute, and it really helps convince popular guests to join me.If you're interested in sponsoring the podcast, please contact me at gregkrinoshow@gmail.com.Instagram: Instagram.com/gregkrinoshow Facebook: Facebook.com/gregkrinoshow

Over the past few years, a number of exciting scientific advances have been made in treating Chronic Lymphocytic Leukemia (CLL). This episode takes a close look at the new treatments and testing being used so that you have the most up to date information for making informed decisions. Our guest is Dr. Danielle Brander.